Caris Life Sciences
A profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 Valuation: €0.0 11.5x EV/Revenue 486.9x EV/EBITDA | round | |
* | N/A | $494m | IPO |
| Total Funding | 000k | ||
| USD | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 18 % | 35 % | 65 % | 44 % | 23 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (103 %) | (85 %) | (49 %) | 2 % | 20 % | 26 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (124 %) | (112 %) | (68 %) | (30 %) | 8 % | 17 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 39 % | 38 % | 28 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Caris Life Sciences is a pioneering company that operates at the intersection of molecular science and artificial intelligence, with a primary focus on revolutionizing cancer care. The company provides comprehensive molecular information to cancer patients and oncologists, aiding in the development of personalized treatment plans. This is achieved by understanding the molecular features of a cancer when the diagnosis is made, which can provide insights into how the cancer may behave and what treatments may be most effective.
Caris Life Sciences' business model is centered on providing high-quality, reliable molecular information to help improve the lives of as many people as possible. The company's clients are primarily oncologists and cancer patients, but also include researchers and payors in the healthcare sector. The company generates revenue by offering its transformative technologies and services to these clients, thereby helping them navigate, advance, and reinvent cancer care.
The company is committed to quality and innovation, and this is reflected in its hiring practices. Caris Life Sciences seeks to employ the brightest minds in scientific, medical, and professional fields to help fulfill the promise of personalized medicine. The company's dedication to its mission is evident in the opportunities it provides to its employees, as well as in the positive experiences shared by team members.
In summary, Caris Life Sciences is a leading innovator in molecular science, using artificial intelligence to revolutionize cancer care by providing comprehensive molecular information to patients, oncologists, researchers, and payors.
Keywords: Molecular Science, Artificial Intelligence, Cancer Care, Personalized Treatment, Oncologists, Cancer Patients, Healthcare Sector, Transformative Technologies, Quality Commitment, Personalized Medicine.